EUVIMEDEUVIMED entdecken
Crossref

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel iD, Myriam Labopin, Urpu Salmenniemi, Gerard Socié, Sergey Bondarenko, Didier Blaise, Nicolaus Kröger, Jan Vydra, Anna Grassi, Francesca Bonifazi, Tomasz Czerw, Achilles Anagnostopoulos und 9 weitere

Cancer · 2023

DOI: 10.1002/cncr.35004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Sebastian Giebel und 20 weiteren Autor:innen. Beteiligte Einrichtung: Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Graft vs Host Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to compare two immunosuppressive strategies, based on the use of either rabbit antithymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCY), as a prophylaxis of graft‐versus‐host disease (GVHD) for patients with acute lymphoblastic leukemia (ALL) in first complete remission who underwent hematopoietic cells transplantation from matched unrelated donors.

Methods

Overall, 117 and 779 adult patients who received PTCY and ATG, respectively, between the years 2015 and 2020 were included in this retrospective study. The median patient age was 40 and 43 years in the PTCY and ATG groups, respectively, and 37% and 35% of patients, respectively, had Philadelphia chromosome‐positive ALL.

Results

In univariate analysis, the cumulative incidence of acute and chronic GVHD did not differ significantly between the study groups. The cumulative incidence of relapse at 2 years was reduced in the PTCY group (18% vs. 25%; p = .046) without a significant impact on nonrelapse mortality (11% vs. 16% in the ATG group; p = .29). The rates of leukemia‐free survival (LFS) and overall survival were 71% versus 59%, respectively ( p = .01), and 82% versus 74%, respectively ( p = .08). In multivariate analysis, the receipt of ATG compared with PTCY was associated with a reduced risk of extensive chronic GVHD (hazard ratio, 0.54; 95% confidence interval, 0.3–0.98; p = .04) and an increased risk of low LFS (hazard ratio, 1.57; 95% confidence interval, 1.01–2.45; p = .045).

Conclusions

The receipt of ATG compared with PTCY, despite the reduced risk of extensive chronic GVHD, is associated with inferior LFS in adults with ALL who undergo hematopoietic cell transplantation from 10/10 human leukocyte antigen‐matched unrelated donors. These findings warrant verification in prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaGraft vs Host DiseaseAdultHumansAntilymphocyte SerumUnrelated DonorsRetrospective StudiesProspective StudiesBone MarrowCyclophosphamideAcute DiseaseTransplantation Conditioning

Stichwörter der Autor:innen

acute lymphoblastic leukemiaallogeneic hematopoietic cell transplantationantithymocyte globulincyclophosphamidematched unrelated donorrelapsesurvival

Substanzen

Antilymphocyte SerumCyclophosphamide

Autor:innen und Institutionen

  • Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
  • Department of Hematology and Cellular Therapy, National Institute of Health and Medical Research Unit UMR-S 938, Sorbonne University and St Anthony Scientific Research Center, Public Assistance Hospital of Paris, St Ant…
  • European Society for Blood and Marrow Transplantation Paris Study Office/CEREST-TC, Paris, France.
  • Stem Cell Transplantation Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Hematology, National Institute of Health and Medical Research Unit U976, Public Assistance Hospital of Paris, St Louis Hospital, University of Paris, Paris, France.
  • RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russia.

ORCID-Profile: Sebastian Giebel, Annalisa Ruggeri, Arnon Nagler

Zitieren

APA

Giebel, S., Labopin, M., Salmenniemi, U., Socié, G., Bondarenko, S., Blaise, D., Kröger, N., Vydra, J., Grassi, A., Bonifazi, F., Czerw, T., Anagnostopoulos, A., Lioure, B., Ruggeri, A., Savani, B., Spyridonidis, A., Sanz, J., Peric, Z., Nagler, A., …, & Mohty, M. (2023). Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. https://doi.org/10.1002/cncr.35004

Vancouver

Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2023. doi:10.1002/cncr.35004

BibTeX
@article{Giebel2023,
  author = {Giebel, Sebastian and Labopin, Myriam and Salmenniemi, Urpu and Socié, Gerard and Bondarenko, Sergey and Blaise, Didier and Kröger, Nicolaus and Vydra, Jan and Grassi, Anna and Bonifazi, Francesca and Czerw, Tomasz and Anagnostopoulos, Achilles and Lioure, Bruno and Ruggeri, Annalisa and Savani, Bipin and Spyridonidis, Alexandros and Sanz, Jaime and Peric, Zinaida and Nagler, Arnon and Ciceri, Fabio and Mohty, Mohamad},
  title = {Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.35004}
}
Kostenlos starten →